Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ADMA with free AI briefings, catalyst countdowns, and dilution alerts.

ADMA · ADMA Biologics Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$124.6M Cash on Hand
CF+ Cash Runway
Follow ADMA by email Get an email when ADMA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADMA, unsubscribe in one click. Privacy

📣 What ADMA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Asceniv™ Primary Immune Deficiency Phase 4 · NCT05070455 Unknown
Bivigam Humoral Immune Response Phase 4 · NCT03164967 Completed
Nabi-IGIV 10% [Immune Globulin Intravenous… Primary Immune Deficiency Disorders (PIDD) Phase 3 · NCT00538915 Completed
Therapeutic Immune Globulin Primary Immune Deficiency Disorder Phase 3 · NCT01814800 Completed
Therapeutic Hepatitis C Immune Globulin Sequelae of Viral Hepatitis Phase 2 · NCT00473824 Terminated
High-titer RSV Immune Globulin RI-001 Upper Respiratory Tract Infection Phase 2 · NCT00632463 Completed
Other Primary Immune Deficiency Disorder N/A · NCT03037359 Unknown

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADMA holds $124.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADMA files for a raise →

👥 Who Owns ADMA

Insiders 3% Institutions (450 holders) 90% Public and other holders 7%
HolderTypeShares% of sharesAs of
STATE STREET CORPORATION Institution (13G, 5%+) 13,675,348 6.16% 2026-09-30
Rubric Capital Management LP Institution (13G, 5%+) 12,352,584 5.57% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 12,110,153 5.46% 2026-03-31
Adam S Grossman
President and CEO, Director · +1.71M options
Insider 2,645,734 1.19% 2026-11-16
Steve Elms
Director · +17,730 options
Insider 2,143,750 0.97% 2026-03-05
Jerrold B Grossman
Director · +17,730 options
Insider 520,459 0.23% 2026-05-27
Kaitlin M. Kestenberg-Messina
COO and SVP, Compliance · +155,801 options
Insider 443,061 0.20% 2026-07-24
Young Kwon
Director · +17,730 options
Insider 263,020 0.12% 2026-02-09
Brad L. Tade
CFO and Treasurer
Insider 232,940 0.10% 2026-02-19
Terry Kohler
CFO and Treasurer · +136,363 options
Insider 143,149 0.06% 2026-07-16
Lawrence P. Guiheen
Director · +41,567 options
Insider 114,589 0.05% 2026-11-16
Alison Cecily Finger
Director · +17,730 options
Insider 45,619 0.02% 2026-02-09

Share count 221,854,389 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ADMA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADMA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.